These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24418411)

  • 1. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.
    Mould E; Berry P; Jamieson D; Hill C; Cano C; Tan N; Elliott S; Durkacz B; Newell D; Willmore E
    Biochem Pharmacol; 2014 Mar; 88(1):58-65. PubMed ID: 24418411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
    Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
    Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
    Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
    Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
    Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
    Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.
    Leahy JJ; Golding BT; Griffin RJ; Hardcastle IR; Richardson C; Rigoreau L; Smith GC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6083-7. PubMed ID: 15546735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination.
    Tavecchio M; Munck JM; Cano C; Newell DR; Curtin NJ
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):155-64. PubMed ID: 21630086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent enantioselective inhibition of DNA-dependent protein kinase (DNA-PK) by atropisomeric chromenone derivatives.
    Clapham KM; Rennison T; Jones G; Craven F; Bardos J; Golding BT; Griffin RJ; Haggerty K; Hardcastle IR; Thommes P; Ting A; Cano C
    Org Biomol Chem; 2012 Sep; 10(33):6747-57. PubMed ID: 22814419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
    Hardcastle IR; Cockcroft X; Curtin NJ; El-Murr MD; Leahy JJ; Stockley M; Golding BT; Rigoreau L; Richardson C; Smith GC; Griffin RJ
    J Med Chem; 2005 Dec; 48(24):7829-46. PubMed ID: 16302822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
    Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
    Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Chao OS; Goodman OB
    Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR.
    Tang XQ; Bi H; Feng JQ; Cao JG
    Acta Pharmacol Sin; 2005 Aug; 26(8):1009-16. PubMed ID: 16038636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
    Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
    Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
    Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
    Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DNA-PK enhances chemosensitivity of B-cell precursor acute lymphoblastic leukemia cells to doxorubicin.
    Alikarami F; Safa M; Faranoush M; Hayat P; Kazemi A
    Biomed Pharmacother; 2017 Oct; 94():1077-1093. PubMed ID: 28821159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance.
    Barancík M; Bohácová V; Sedlák J; Sulová Z; Breier A
    Eur J Pharm Sci; 2006 Dec; 29(5):426-34. PubMed ID: 17010577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair.
    Sunada S; Kanai H; Lee Y; Yasuda T; Hirakawa H; Liu C; Fujimori A; Uesaka M; Okayasu R
    Cancer Sci; 2016 Sep; 107(9):1250-5. PubMed ID: 27341700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J; Wang FP; Wei H; Liu G
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.